Table 3.
Benefits | |
Able to tangibly experience treatment efficacy through the sustained period of macular dryness | • Patients know that their treatment is working when their injection intervals increase • Treatment intervals can be adjusted to meet patient needs while maximizing the period of dryness |
Decrease in emotional burden associated with receiving intraocular injections | • Since their injection schedule is determined months ahead, patients are emotionally prepared on the day of injection, decreasing their emotional burden toward treatment • Patients become proactive toward treatment as their symptoms stabilize with the preventive injections |
Decrease in patient/caregiver time burden | • Scheduling visits with patients’ family members is easier as the majority of patients are elderly and require accompaniment by their family members • The number of treatments that had to be postponed because family members were unable to accompany patients to the clinic has decreased • Visits only have to be once every few months |
Issues | |
Increased financial burden for the patients | • The financial burden may increase since the number of injections increases with T&E • Explaining the administration method is difficult without any aides, which makes it more difficult for patients to accept the financial burden • It is difficult to explain to patients how long they need to continue their injections with the lack of long-term evidence |
Worry of complications | • The risk of infections may increase with the increased number of injections |
Abbreviations: PRN, pro re nata; T&E, treat-and-extend.